Denali Therapeutics Inc.
http://www.denalitherapeutics.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Denali Therapeutics Inc.
After Aducanumab: Finding New Treatments For Neurodegenerative Diseases
As a freshman interested in neurobiology at Joseph Fourier University in Grenoble, Virginie Buggia-Prevot knocked on the lab door of an esteemed neurosurgeon and professor conducting research on deep brain stimulation. She was hooked; following a PhD in neurobiology and a post doc at the University of Chicago, Buggia-Prevot joined MD Anderson’s Neurodegeneration Consortium, managing strategic alliances and working on drug discovery. In November, she joined Valo as director of neurology discovery, an opportunity to bring new research in neurodegeneration to bear on patients’ lives.
Biogen Bets Big To Bag Sage Depression And Tremor Drugs
Rather than hitting the acquisition trail, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.
Biogen Builds Out Parkinson's Pipeline With Denali Deal
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Tech Transfer Roundup: Universities And Biotechs Continue To Look For Ways To Combat COVID-19
AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- F-star Gamma
- Incro Pharmaceuticals